BIOMAT Database Logo BIOMAT Database Logo

The central anticholinergic syndrome: management with physostigmine. 1975

R P Granacher

UI MeSH Term Description Entries
D008297 Male Males
D010276 Parasympatholytics Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. Antispasmodic,Antispasmodic Agent,Antispasmodic Drug,Antispasmodics,Parasympathetic-Blocking Agent,Parasympathetic-Blocking Agents,Parasympatholytic,Parasympatholytic Agent,Parasympatholytic Drug,Spasmolytic,Spasmolytics,Antispasmodic Agents,Antispasmodic Drugs,Antispasmodic Effect,Antispasmodic Effects,Parasympatholytic Agents,Parasympatholytic Drugs,Parasympatholytic Effect,Parasympatholytic Effects,Agent, Antispasmodic,Agent, Parasympathetic-Blocking,Agent, Parasympatholytic,Agents, Antispasmodic,Agents, Parasympathetic-Blocking,Agents, Parasympatholytic,Drug, Antispasmodic,Drug, Parasympatholytic,Drugs, Antispasmodic,Drugs, Parasympatholytic,Effect, Antispasmodic,Effect, Parasympatholytic,Effects, Antispasmodic,Effects, Parasympatholytic,Parasympathetic Blocking Agent,Parasympathetic Blocking Agents
D010830 Physostigmine A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. Eserine
D011605 Psychoses, Substance-Induced Psychotic organic mental disorders resulting from the toxic effect of drugs and chemicals or other harmful substance. Psychoses, Drug,Psychoses, Toxic,Substance-Induced Psychoses,Toxic Psychoses,Drug Psychoses,Psychoses, Substance Induced,Substance Induced Psychoses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

R P Granacher
Central anticholinergic syndrome or central physostigmine responsive syndrome?
November 1997, European journal of anaesthesiology,
R P Granacher
[Central anticholinergic syndrome and its therapy with physostigmine].
November 1975, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
R P Granacher
Hepatic encephalopathy--a physostigmine-reactive central anticholinergic syndrome?
February 1999, European journal of anaesthesiology,
R P Granacher
Reversal of central anticholinergic syndrome in man by physostigmine.
November 1968, JAMA,
R P Granacher
Reversal of tricyclic-overdosage-induced central anticholinergic syndrome by physostigmine.
September 1976, The American journal of psychiatry,
R P Granacher
Central anticholinergic syndrome due to Jimson weed physostigmine: therapy revisited?
January 1998, Journal of toxicology. Clinical toxicology,
R P Granacher
Physostigmine: going ... going ... gone? Two cases of central anticholinergic syndrome following anaesthesia and its treatment with physostigmine.
July 1997, European journal of anaesthesiology,
R P Granacher
Physostigmine is the antidote for anticholinergic syndrome.
March 2015, Journal of medical toxicology : official journal of the American College of Medical Toxicology,
R P Granacher
Anticholinergic poisoning: treatment with physostigmine.
September 1973, Pediatrics,
R P Granacher
[Physostigmine for treatment of central anticholinergic syndrome: a report of 3 cases (author's transl)].
July 1980, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
Copied contents to your clipboard!